Vancouver, BC (PRWEB) November 19, 2014
Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) is pleased to report that Dr. Raj Attariwala was recently quoted in a TIME Magazine story titled “ Driving While High” by TIME journalist Eliza Gray. Dr. Attariwala is Cannabix Technologies’ Chief Engineer and co-founder of the Cannabix Marijuana Breathalyzer. The author of the story, Eliza Gray, has contributed a series of marijuana related articles for TIME Magazine.
The TIME story, Driving While High, examines and provides thorough insight into the increasing problem of driving while under the influence of marijuana. The article states: “It is no surprise that solving the problem is a priority for public officials, since there is evidence to suggest that driving high is a real danger.”
Furthermore, the article quotes and makes mention of Dr. Attariwala and Cannabix President Kal Mahli: “A retired Canadian police officer (Mahli) and a physician (Attariwala) have teamed up to create a new Breathalyzer that will detect marijuana use in the past two hours, a decent measure of impairment since pot’s effects are usually felt for about two to three hours after use. Co-developer Dr. Raj Attariwala says the technology will get more precise as legalization spurs research.”
For the TIME article please visit cannabixtechnologies.com and the link below.
Link to TIME article: http://time.com/3455621/driving-while-high/
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is the developer of the patent pending Cannabix Marijuana Breathalyzer for law enforcement and the workplace. The Cannabix Marijuana Breathalyzer drug-impairment recognition system is based on breath testing technology that has been developed to test individuals for recent consumption of the THC component of marijuana. Cannabix is advancing its products to enable law enforcement personnel to use this technology to enhance detection of marijuana impaired driving offences on North American roads at a time when marijuana is becoming legal in many jurisdictions. Cannabix is working to develop a drug-testing device that will detect Tetrahydrocannabinol (THC- the psychoactive component of marijuana that causes intoxication) using breath samples. The device would be used to provide detection of THC at the roadside to identify drivers intoxicated by the recent use of marijuana. The device will also be useful for other practical applications such as testing employees in the workplace where intoxication by THC can be hazardous. The device is currently in prototype development and the Company is rapidly developing this technology.
We seek Safe Harbor.
On behalf of the Board of Directors
Cannabix Technologies Inc.
For further information, contact the Company's CEO, Rav Mlait 604-551-7831 email at info(AT)cannabixtechnologies.com
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (v) the ability of the Company to develop and market its future product; and (vi) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built or proceed. There is no assurance that existing “patent pending” technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.